Back to Health

Who Should Avoid Rilpivirine?

Who Should Avoid Rilpivirine?
Bareback Guide 4 May 2026

Rilpivirine is well tolerated and comes with more restrictions than most antiretrovirals. Knowing whether you fall into one of them is what determines whether it suits you.

Who cannot start on it?

Anyone beginning treatment with a viral load above 100,000 copies, or with a low CD4 count. Effectiveness falls in that group and virological failure rates rise, which is why the restriction exists in its licensing.

Does that apply to switching?

No. Someone already suppressed can switch to rilpivirine regardless of what their viral load was originally. The restriction concerns starting treatment, and this is where the drug fits best.

Who is excluded by acid-reducing medication?

Anyone taking a proton pump inhibitor they cannot stop. These are contraindicated outright rather than needing spacing, so for someone with reflux disease requiring continuous treatment, a different antiretroviral is the answer.

Who is excluded by eating patterns?

Anyone whose meals are unpredictable. The five hundred calorie requirement is strict, and shift work, irregular eating, appetite problems or intermittent fasting all make this a poor fit.

Is that a judgement about you?

No, a matching exercise. Plenty of people eat irregularly for entirely good reasons, and choosing a drug without a food requirement is sensible rather than a concession.

Who is excluded by other interactions?

Anyone taking rifampicin, or a strong enzyme-inducing anticonvulsant such as carbamazepine or phenytoin, or St John's wort they will not stop.

What about existing non-nucleoside resistance?

Depends on the pattern. Resistance to rilpivirine overlaps with resistance to other drugs in the class, and resistance testing determines whether it is usable.

What about adherence?

Its moderate resistance barrier means repeated missed doses carry more risk than with dolutegravir or boosted darunavir. Where dosing is likely to be irregular, a higher-barrier regimen is safer.

What about pregnancy?

Levels fall during pregnancy, risking inadequate concentrations. It is generally not a preferred option and may need monitoring or changing. Raise a pregnancy or a plan for one early.

What about hepatitis B?

Rilpivirine has no activity against it. The two-drug combination with dolutegravir provides no hepatitis B cover, which matters for anyone with chronic infection considering that regimen.

What about heart conduction problems?

Caution where the QT interval is already prolonged or where other QT-prolonging drugs are involved. At the licensed dose this is usually a matter for review rather than exclusion.

When is it a good choice?

For someone already suppressed who wants to come off a boosted regimen, who eats regularly, who does not need acid suppression, and who has no relevant resistance. Also as half of the injectable regimen, where the food requirement disappears entirely.

What are the alternatives?

Integrase inhibitors such as dolutegravir and bictegravir, first-line with higher barriers and no food or acid requirements. Doravirine, the other modern non-nucleoside, with no food restriction. Boosted darunavir where a very high barrier is needed.

Can you switch away easily?

Yes. Switching is routine and suppression is maintained provided the new regimen is fully active. A decision now is not permanent.

Who decides?

You do, with a clinician. If the meal requirement is not working for you, that is sufficient reason to change and does not need further justification.